AIM ImmunoTech (AIM) Stock Soars Nearly 100% on Japanese Cancer Treatment Patent Approval
Quick Overview AIM ImmunoTech shares jumped 97.18% Wednesday following Japanese patent approval for its cancer therapy approach The approved patent protects the use of Ampligen combined with checkpoint inhibitor drugs for various cancer types, with …